---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026739"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:39:24.307181+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset

## Summary
- In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.
- In subset treated within 3 days of symptom onset, 1.0 log viral load decline seen at Day 5.
- Results support further development of EDP-235 for COVID-19.
- Updated corporate presentation with additional SPRINT analyses posted on website June 7, 2023.

## SEC filing metadata
- accession: 0000950170-23-026739
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/0000950170-23-026739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/enta-20230607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026739
- JSON: https://secwatch.observer/filing/0000950170-23-026739.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.